E-resources
Peer reviewed
-
Chae, Heejung; Kim, Deokhoon; Yoo, Changhoon; Kim, Kyu-pyo; Jeong, Jae Ho; Chang, Heung-Moon; Lee, Sang Soo; Park, Do Hyun; Song, Tae Jun; Hwang, Shin; Kim, Ki-Hun; Song, Gi-Won; Ahn, Chul Soo; Lee, Jae Hoon; Hwang, Dae Wook; Kim, Song Cheol; Jang, Se Jin; Hong, Seung-Mo; Kim, Tae Won; Ryoo, Baek-Yeol
European journal of cancer (1990), October 2019, 2019-10-00, 20191001, Volume: 120Journal Article
In biliary tract cancer (BTC), standard chemotherapy has limited benefit and no molecular targeted agents have been approved. This study investigated the genetic profile of BTC to identify potential new therapeutic targets and predictive biomarkers. Targeted exome sequencing was performed for 124 patients with BTC gallbladder cancer (GBC), 25; intrahepatic cholangiocarcinoma (ICC), 55; extrahepatic cholangiocarcinoma (ECC), 44. Survival analysis was performed in 112 patients who received palliative chemotherapy for locally unresectable or metastatic disease. Genetic alterations were observed in 104 patients (83.8%); the most commonly mutated genes were TP53 (44.4%), KRAS (29.0%), ARID1A (12.1%) and IDH1 (9.7%). IDH1/2 mutations appeared more frequently in ICC (23.6%, P = 0.0002) than in GBC (4.0%) or ECC (2.3%), while ERBB2/3 mutations were found only in GBC (20.0%) and ECC (11.4%). Patients harbouring TP53 mutations had shorter overall survival (OS; median 15.2 vs. 37.8 months, P = 0.018), while IDH1 mutations showed a tendency for longer progression-free survival (PFS; 10.6 vs. 6.1 months, P = 0.124). Potentially actionable genetic alterations were found in 54.8%, and 7.1% received appropriate molecular targeted therapy in the clinical trial setting. Germline or somatic mutations in DNA damage repair (DDR) genes were found in 63.5% of patients and were significantly associated with longer PFS (6.9 vs. 5.7 months, P = 0.013) and OS (21.0 vs. 13.3 months, P = 0.009) in patients who received first-line platinum-containing chemotherapies (n = 88). A subgroup of patients with BTC may benefit from targeted therapy by the aid of genetic information. In particular, DDR alterations may be a predictive biomarker for response to platinum-containing chemotherapy in patients with BTC. •We examined genetic landscape of biliary tract cancer with targeted sequencing.•Certain genetic mutations were associated with clinical outcomes.•More than half of patients harboured at least one potentially actionable alteration.•DNA damage repair gene alterations were associated with a better response to platinum-based treatment.
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.